Dr Wang highlights the evidence on Acalabrutinib and Other Novel Therapies in Mantle Cell Lymphoma
Dr. Michael Wang, US
Dr. Michael Wang, MD, Puddin Clarke Endowed Professor at MD Anderson Cancer Centre in the United States, provided insights on Acalabrutinib and Other Novel Therapies in Mantle Cell Lymphoma (MCL). He discussed on trial related to Acalabrutinib and newer therapies. These insights contribute to the evolving landscape of novel therapies in MCL and benefit clinicians and researchers in the field.
Explore more videos
Translating Data Into Practice
Dr. Ghazi Alotaibi, KSA
MCL Management in Clinic
Dr. Salem Alshemmari, Kuwait
Critical Evaluation of BTKis in CLL
Dr. George Follows, UK